BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells.
BRCA1 is a tumor suppressor which plays a crucial role in the repair of DNA double-strand breaks, and its abnormality is responsible for hereditary ovarian cancer syndrome. It has recently been reported that reduced expression of BRCA1 is also common in sporadic ovarian carcinoma via its promoter hypermethylation, and that ovarian carcinoma patients negative for BRCA1 expression showed favorable prognosis. To address if BRCA1 expression plays a role in the chemotherapeutic response, we analyzed the effect of BRCA1 suppression on the sensitivity to cisplatin and paclitaxel in ovarian cancer cells. Specific siRNA for BRCA1 gene was transfected into 3 ovarian cancer cell lines with various p53 status. Reduced expression of BRCA1 by transfection of BRCA1-siRNA resulted in a 5.3-fold increase in sensitivity to cisplatin in p53-wild A2780 cells, but not in p53-mutated A2780/CDDP and p53-deleted SKOV3 cells. Regarding the sensitivity to paclitaxel, BRCA1 suppression caused no significant changes in all the 3 cell lines. For ionizing radiation sensitivity, BRCA1 suppression also showed a significant higher sensitivity in A2780 cells. Growth curve and cell cycle analyses showed no significant differences between BRCA1-siRNA-transfected A2780 cells and control cells. However, cisplatin treatment under suppression of BRCA1 showed a significantly increased apoptosis along with up-regulation of p53 and p21 in A2780 cells. Accordingly, reduced expression of BRCA1 enhances the cisplatin sensitivity and apoptosis via up-regulation of p53 and p21, but does not affect the paclitaxel sensitivity. Expression of BRCA1 might be an important biomarker for cisplatin resistance in ovarian carcinoma.
Horiuchi
Akiko
A
Department of Obstetrics and Gynecology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
Wang
Cuiju
C
Kikuchi
Norihiko
N
Osada
Ryosuke
R
Nikaido
Toshio
T
Konishi
Ikuo
I
J Natl Cancer Inst. 2000 Apr 5;92(7):564-9
10749912
Int J Oncol. 2002 Apr;20(4):845-53
11894135
J Clin Oncol. 2002 Jan 15;20(2):463-6
11786575
Trends Pharmacol Sci. 2005 Mar;26(3):113-6
15749154
Oncogene. 1999 Mar 18;18(11):1957-65
10208417
J Pathol. 2004 Feb;202(2):215-23
14743504
Oncogene. 2003 Apr 24;22(16):2396-404
12717416
Oncogene. 2000 Dec 11;19(53):6152-8
11156529
J Biol Chem. 2004 Jul 23;279(30):31251-8
15159397
Hum Mol Genet. 2004 Oct 15;13(20):2443-9
15317748
J Biol Chem. 1998 May 15;273(20):12250-8
9575175
Jpn J Cancer Res. 1986 Sep;77(9):941-5
2429947
J Natl Cancer Inst. 2004 Nov 17;96(22):1659-68
15547178
Hum Mol Genet. 2003 Apr 1;12 Spec No 1:R113-23
12668603
Cancer Res. 1998 Mar 15;58(6):1120-3
9515792
Cancer Res. 2003 Oct 1;63(19):6221-8
14559807
Lab Invest. 2003 Jun;83(6):861-70
12808121
EMBO J. 2002 Jul 15;21(14):3863-72
12110597
Nat Genet. 1995 Apr;9(4):439-43
7795652
Clin Cancer Res. 1998 Oct;4(10):2433-7
9796975
Nat Genet. 1997 Jul;16(3):298-302
9207798
Oncogene. 1999 Jan 7;18(1):263-8
9926942
Nature. 2000 Nov 23;408(6811):429-32
11100717
Cancer Res. 2000 Oct 1;60(19):5329-33
11034065
Science. 1994 Oct 7;266(5182):120-2
7939630
J Cancer Res Clin Oncol. 1986;112(3):210-5
3097024
J Mammary Gland Biol Neoplasia. 1998 Oct;3(4):431-45
10819537
J Natl Cancer Inst. 2002 Jan 2;94(1):61-7
11773283
Nat Genet. 1995 Apr;9(4):444-50
7795653
Int J Cancer. 2000 Aug 1;87(3):317-21
10897034
Gynecol Oncol. 2000 Mar;76(3):294-300
10684699
Cell. 1996 Jun 28;85(7):1009-23
8674108
Oncogene. 1999 Nov 11;18(47):6605-14
10597265
JAMA. 2000 May 3;283(17):2260-5
10807385
Science. 1994 Oct 7;266(5182):66-71
7545954
N Engl J Med. 1996 Nov 7;335(19):1413-6
8875917
Breast Cancer Res Treat. 2003 Mar;78(1):45-50
12611456
Br J Cancer. 2003 Apr 22;88(8):1285-91
12698198